Pfizer (PFIZER.NS) Aandeel Koers
Pfizer Koers
De omzet is de afgelopen 19 jaar met 7,0% per jaar gegroeid tot 25,20 Miljard INR. De winst per aandeel is de afgelopen 19 jaar met 10,6% per jaar gegroeid. De nettowinstmarge van Pfizer ligt op 28,7% en is ten opzichte van 23,5% enkele jaren eerder gestegen. Pfizer biedt momenteel een dividendrendement van circa 3,37%. De uitkeringsratio ligt rond 37% van de winst. Het dividend is de afgelopen 19 jaar met 9,7% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 6.222,00 INR — dat impliceert 61,4% boven de huidige koers. Van de 8 analisten geven 5 het aandeel een koopadvies — per saldo een Kopen-consensus.
Pfizer aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Pfizer bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Pfizer
The business model of Pfizer Ltd revolves around pharmaceutical research, development, manufacturing, and sales. As a leading global biopharmaceutical company, Pfizer focuses on discovering breakthrough medicines and vaccines for various health conditions. With a diverse portfolio, Pfizer aims to improve patient lives and promote better health outcomes by investing in innovative research and development. Through strategic partnerships and collaborations, Pfizer strives to advance healthcare solutions while maintaining a strong commitment to delivering quality products. By upholding high standards of scientific integrity and ethical business practices, Pfizer continues to contribute to the well-being of individuals worldwide.
Pfizer Ltd is primarily active in the pharmaceutical industry. Its core business focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. Pfizer Ltd is a renowned global pharmaceutical company, known for its breakthrough medicines and innovative therapies across various therapeutic areas. With a strong presence in the healthcare sector, Pfizer Ltd strives to enhance and improve the well-being of individuals worldwide.
The main competitors of Pfizer Ltd in the market include pharmaceutical companies such as Johnson & Johnson, Merck & Co., GlaxoSmithKline, and Novartis.
Pfizer Ltd. is a renowned pharmaceutical company with a rich history and background. Founded in 1849, Pfizer has evolved into a leading global player in the healthcare industry. With headquarters in the United States, the company has expanded its reach worldwide, including operations in India through Pfizer Ltd. Pfizer Ltd. is committed to discovering, developing, and manufacturing innovative medicines, vaccines, and consumer healthcare products. The company's relentless pursuit of medical advancements and dedication to improving people's lives has earned Pfizer Ltd. a strong reputation and recognition as a trusted name in the pharmaceutical sector.
Pfizer Ltd, a renowned pharmaceutical company, has achieved several significant milestones over the years. Notably, Pfizer is credited with the development of life-saving drugs like Viagra, Lipitor, and Zoloft, which have had a tremendous impact on global healthcare. Pfizer's contributions in the fields of immunology, oncology, and cardiology have not gone unnoticed, establishing the company as a leader in medical advancements. Pfizer's commitment to research and innovation has resulted in groundbreaking treatments, ensuring better clinical outcomes for patients worldwide. This dedication to excellence and their bold pursuit of scientific breakthroughs have made Pfizer Ltd a trusted and influential player in the pharmaceutical industry.
Pfizer Ltd, a leading pharmaceutical company, has a prominent presence in various countries and regions globally. The company operates in several key markets, including the United States, Europe, Asia-Pacific, Latin America, and Africa. With its headquarters in New York, Pfizer Ltd has established a strong foothold in the United States, utilizing its extensive network for research, development, and distribution of innovative healthcare solutions. Additionally, Pfizer Ltd's operations span across Europe, where it operates in numerous countries, catering to diverse healthcare needs. Further, the company's presence extends to the Asia-Pacific region, Latin America, and Africa, emphasizing its commitment to addressing global health challenges effectively.
Pfizer Ltd represents a set of core values and a strong corporate philosophy. As a renowned pharmaceutical company, Pfizer Ltd is committed to innovation and scientific advancement in the healthcare industry. The company believes in providing high-quality and safe medications to improve patient outcomes. Pfizer Ltd also emphasizes integrity, ethical practices, and transparency in all aspects of its operations. With a dedication to research and development, Pfizer Ltd aims to discover and deliver life-saving and life-enhancing therapies for people worldwide. This commitment, along with a customer-centric approach, makes Pfizer Ltd a trusted name in the pharmaceutical sector.
Analisten hanteren momenteel een gemiddeld koersdoel van 6.389,08 INR voor het aandeel Pfizer (mediaan: 6.222,00 INR), oftewel +65,7 % ten opzichte van de laatste koers. De consensus is gebaseerd op 8 analistenratings.
9 analisten beoordelen het aandeel Pfizer momenteel: 6 adviseren kopen, 3 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Pfizer op 37,63 EUR (3.856,00 INR).
Het aandeel Pfizer (PFIZER.NS) is genoteerd aan 2 beurzen, waaronder: NSE (Indien) (PFIZER.NS).
Pfizer Ltd is a pharmaceutical company that focuses on the research, development, and marketing of products for the prevention and treatment of diseases. It has a global customer base and operates in various medical fields such as oncology, immunology, neurology, and infectious diseases. The company offers a wide range of medications, from well-established drugs to new therapies and biotechnological products. Its business model is centered on growth and profitability, with investments in research and development to remain competitive. Pfizer Ltd is organized into different divisions, including oncology, infectious diseases, immunology, and neurology, and also engages in the development of biotechnology products. Its products are marketed globally through pharmaceutical distribution channels. Overall, Pfizer Ltd strives to improve the health of patients worldwide through the development and marketing of innovative therapies.
De omzet van Pfizer bedraagt 25,20 Miljard INR. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Pfizer bedraagt 7,22 Miljard INR. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Pfizer bedraagt momenteel 24,42. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Pfizer-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Pfizer bedraagt momenteel 7,00. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Pfizer-aandeel.
De Eulerpool Kwaliteitsscore voor Pfizer is 5/10.
De ISIN van Pfizer is INE182A01018. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
Het tickersymbool van Pfizer is PFIZER.NS. Onder dit beurstickersymbool wordt het Pfizer-aandeel op de beurs verhandeld.
Pfizer aandeel
Pfizer Peer Group
Pfizer Ticker
Pfizer FIGI
Alle fundamentals en diepgaande analyse van Pfizer
Onze aandelenanalyse van het Pfizer-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Pfizer. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: